Paving the way for a better understanding of the pathophysiology of gait impairment in myotonic dystrophy: a pilot study focusing on muscle networks

Table 1 DM1 clinical–demographic characteristics

gender, age	CTG expansion^a	DM1 onset	Comorbidities	CRS	MSS
F, 49y	E2	25y	headache	2	2
F, 23y	E2	16y	nasal turbinate stenosis	2	2
M, 19y	E2	17y	–	1	3
F, 45y	E2	22y	BS1, OSAS	2	3
F, 29y	E2	15y	headache	2	2
F, 17y	E2	15y	–	1	3
F, 65y	E2	30y	headache, HBV–hepatitis, slight respiratory failure	2	2

Legend: CRS (Clinical rating scale) for DM1 (Dystrophic Myotonia type 1): 1 = presence of myotonia and/or mild functional weakness without functional impairment; 2 = moderate muscle weakness leading to some degree of functional impairment; 3 = muscle weakness with severe functional impairment and in some cases resulting in the subjects being bound to a wheelchair; 4 = bedridden. MSS (myotonia severity scale) for DM1 from 0 (absence of myotonia) to 4 (the worst myotonia experienced). BS1 Brugada syndrome type 1.OSAS Obstructive Sleep Apnea Syndrome. ^a Range of CTG expansion: E1: 20–150; E2: 150–1000; E3: > 1000

ISSN: 1743-0003